Phase II study on 9-nitrocamptothecin (RFS2000) in patients with advanced or metastatic urothelial tract tumors

Maja de Jonge; JP Droz; L Paz-Ares; AT van Oosterom; Ronald de Wit; P Chollet; B Baron; D Lacombe; K Mettinger; P Fumoleau

doi:10.1023/B:DRUG.0000026260.24275.02

Phase II study on 9-nitrocamptothecin (RFS2000) in patients with advanced or metastatic urothelial tract tumors

Maja de Jonge
, JP Droz
, L Paz-Ares
, AT van Oosterom
, Ronald de Wit
, P Chollet
, B Baron
, D Lacombe
, K Mettinger
, P Fumoleau

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	329-333
Number of pages	5
Journal	Investigational New Drugs
Volume	22
DOIs	https://doi.org/10.1023/B:DRUG.0000026260.24275.02
Publication status	Published - 2004

Research programs

EMC MM-03-86-08

Access to Document

10.1023/B:DRUG.0000026260.24275.02

http://hdl.handle.net/1765/69844

Cite this

@article{ad70aa7b53454054aee43d7d849b7ec5,

title = "Phase II study on 9-nitrocamptothecin (RFS2000) in patients with advanced or metastatic urothelial tract tumors",

author = "\{de Jonge\}, Maja and JP Droz and L Paz-Ares and \{van Oosterom\}, AT and \{de Wit\}, Ronald and P Chollet and B Baron and D Lacombe and K Mettinger and P Fumoleau",

year = "2004",

doi = "10.1023/B:DRUG.0000026260.24275.02",

language = "Undefined/Unknown",

volume = "22",

pages = "329--333",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

}

TY - JOUR

T1 - Phase II study on 9-nitrocamptothecin (RFS2000) in patients with advanced or metastatic urothelial tract tumors

AU - de Jonge, Maja

AU - Droz, JP

AU - Paz-Ares, L

AU - van Oosterom, AT

AU - de Wit, Ronald

AU - Chollet, P

AU - Baron, B

AU - Lacombe, D

AU - Mettinger, K

AU - Fumoleau, P

PY - 2004

Y1 - 2004

U2 - 10.1023/B:DRUG.0000026260.24275.02

DO - 10.1023/B:DRUG.0000026260.24275.02

M3 - Article

C2 - 15122081

SN - 0167-6997

VL - 22

SP - 329

EP - 333

JO - Investigational New Drugs

JF - Investigational New Drugs

ER -